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Abstract
Objective: Individuals with dual diagnoses benefit from participation in mutual-help groups,
though it is unclear how much such participation contributes to outcomes when accounting for
utilization of treatment. Methods: We used mixed-model regressions to examine associations
between participation in mutual-help groups reported at 6-month, 1-year, and 2-year follow-ups
with substance use and psychiatric outcomes among outpatients with dual diagnoses (N=304),
while controlling for amounts of substance use disorder and mental health outpatient treatment.
Results: Follow-up rates were 81%, 82%, and 84% at 6 months, 1 year, and 2 years,
respectively. Mean involvement in mutual-help groups (scale of 0-14) ranged between 4.6 (SD =
4.5) and 6.1 (SD = 4.5). When controlling for baseline status and treatment amounts, more
mutual-help group meeting attendance, F(1, 692.99) = 13.98, p < 0.001, and involvement, F(1,
602.72) = 19.32, p < 0.001, were associated with fewer days of alcohol use. Likewise, after
controlling for baseline status and treatment amounts, more mutual-help group meeting
attendance, F(1, 652.82) = 4.57, p = 0.03, and involvement, F(1, 504.35) = 5.94, p =0.02, were
associated with less drug use. Mutual-help group participation was not associated with number of
psychiatric symptoms. Mental health treatment was associated with fewer days of alcohol use,
F(1, 650.17) = 4.58, p = 0.03. Conclusions: Facilitating mutual-help group involvement among
individuals with dual diagnoses, as well as attendance at more meetings, is of potential benefit to
reducing alcohol and drug use.

Keywords dual diagnosis, mutual-help groups, treatment, substance use and psychiatric
outcomes
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Research shows that mutual-help groups are beneficial to individuals with dual diagnoses
(Bogenschutz, Geppert, & George, 2006; Magura et al., 2003; Moos, Schaefer, Andrassy, &
Moos, 2001). For example, attending more mutual-help group meetings is associated with higher
rates of abstinence and remission from drugs and alcohol (Gossup, Stewart, & Marsen, 2008;
Weiss et al., 2005). These studies, however, have not considered the impact of mutual-help
groups on psychiatric outcomes, controlled for amounts of treatment utilization, or considered
other indicators of mutual-help group participation beyond number of meetings. We address
these issues by examining whether mutual-help group participation is associated with better
substance use and psychiatric outcomes among individuals with dual diagnoses when amounts of
substance use disorder and mental health treatment are also considered.
Studies that have controlled for treatment utilization have primarily sampled individuals
with substance use disorders only. Attending more mutual-help group meetings was associated
with better substance use outcomes when treatment amount was controlled, whereas amount of
outpatient care was not independently associated with outcomes (Moos et al., 2001; Ouimette,
Moos, & Finney, 1998). These and other studies (Ritsher, McKellar, Finney, Otilingam, &
Moos, 2002) suggest that, among individuals with substance use disorders only, attending more
mutual-help group meetings is beneficial for substance use outcomes, above and beyond the
influence of treatment utilization.
There is limited literature on the potential effects of mutual-help groups when controlling
for treatment utilization among individuals with dual diagnoses. Treatment may better address
individuals’ dual substance use and psychiatric conditions, whereas mutual-help groups may not
address psychiatric conditions (Jordan, Davidson, Herman, & Bootsmiller, 2002; Satel, Becker,
& Dan, 1993). An exception is dual-focused mutual-help groups, which have limited availability
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(Timko, Sutkowi, Cronkite, Makin-Byrd, & Moos, 2011). The focus on substance use disorders
in most mutual-help groups may help substance use outcomes more so than psychiatric
outcomes. Among patients with dual diagnoses, with treatment utilization controlled, mutualhelp group attendance has been associated with a greater likelihood of abstinence (Laudet et al.,
2004). Psychiatric symptoms were not assessed, though, leaving open the question of whether
mutual-help group participation contributes to improved psychiatric outcomes when accounting
for treatment among individuals with dual diagnoses.
Determining which outcomes are associated with mutual-help group participation is
important for providers working with patients with dual diagnoses. If mutual-help group
participation does not boost psychiatric outcomes, additional referral options for mental health
conditions may be needed. Also, examining indicators of mutual-help group participation beyond
meeting attendance is important for understanding whether providers need to facilitate
involvement in mutual-help groups (sponsorship, service) for individuals with dual diagnoses.

Present Study
In a sample of individuals with dual diagnoses, we examined associations among
treatment amounts, mutual-help group participation, and substance use and psychiatric outcomes
using data collected at treatment intake and follow-ups. Specifically, we examined whether
mutual-help group participation (number of meetings attended, overall involvement in 12-step
practices) over three follow-up points (6 months, 1 year, and 2 years post-intake) was associated
with better substance use (fewer days of alcohol and drug use) and psychiatric (fewer symptoms)
outcomes. These associations were examined after considering patients’ baseline status and
amounts of substance use disorder, and mental health treatment obtained during the study period.

Dual Diagnosis, Mutual-Help Use, and Outcomes

6

METHODS
Participants
The sample included 304 patients with dual diagnoses (of 343 approached) entering
outpatient mental health treatment in the Department of Veterans Affairs (VA) in northern
California. Treatment was multidisciplinary, reflected evidence-based practices, and taught
skills such as symptom and stress management. Follow-up rates at 6 months, 1 year, and 2 years
were 81% (n=238), 82% (n=241), and 84% (n=238), respectively, among patients not known to
be incarcerated or to have died. Compared to participants not followed, the only significant
differences were that those followed at 6 months had more education at baseline (13.6 vs. 12.9
years), and those followed at 2 years were older (51.7 vs. 49.0 years old) and more often married
(13.2% vs. 4.4%) at baseline (all p’s<.05).
Demographic and clinical characteristics. At baseline, the sample was 91.4% male,
51.0% Caucasian, 45.2% employed, and 11.3% married. On average, participants were 51.1
years old (SD=8.9) and had 13.5 years of education (SD=1.9). According to the medical record
at baseline, psychiatric diagnoses were: major depression (50.5%), bipolar disorder (11.1%),
PTSD (35.9%), other anxiety disorder (24.7%), schizophrenia or schizoaffective disorder
(10.1%), and other psychiatric disorder (16.2%); the total is higher than 100% because some
patients had more than one disorder. These patients had alcohol use disorders only (11.1%), drug
use disorders only (23.4%), or both alcohol and drug use disorders (65.5%). The main drugs of
choice were cocaine, cannabis, and amphetamines.
Prior to enrollment, there was a complete discussion with potential participants and
informed consent was obtained. The study was conducted in accordance with the Declaration of

Dual Diagnosis, Mutual-Help Use, and Outcomes

7

Helsinki, and the Stanford University Institutional Review Board approved and monitored the
study.

Measures
Baseline. At baseline, self-reports regarding patients’ demographics and substance use
and psychiatric status were obtained by trained research assistants. Items assessing substance use
and psychiatric status, using the time period of the previous 30 days, were taken from the
Addiction Severity Index (ASI; McLellan, Luborsky, Woody, & O’Brien, 1980; McLellan,
Luborsky et al., 1985; McLellan, Kushner et al., 1985). Participants reported the number of days
in the past 30 they used alcohol (M=9.2, SD=8.3) and drugs (M=13.7, SD=13.6), and the number
of psychiatric symptoms, each measured dichotomously, they had experienced in the past month
(Angarita et al., 2007; Timko, Cronkite, McKellar, Zemore, & Moos, 2013). Psychiatric
symptoms included depression, anxiety/tension, hallucinations, violent behavior, thoughts of
suicide, and concentration difficulties (M=2.2 symptoms, SD=1.4).
Follow-up. Follow-up assessments, conducted by trained research assistants over the
phone at 6 months, 1 year, and 2 years after treatment intake, covered patients’ mutual-help
group participation since the last assessment, and substance use and psychiatric status in the past
30 days. Treatment utilization was assessed with self-reports and medical records.
Treatment utilization. At each follow-up, the number of VA substance use disorder and
mental health outpatient sessions the patient attended since the previous assessment was obtained
from the medical record; the numbers of non-VA sessions were obtained from self-report. To
determine whether treatment sessions were substance use disorder- or mental health-focused, VA
stop codes were used; stop codes are outpatient workload identifiers that indicate the main
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clinical group responsible for care. Use of stop codes separates substance use disorder and
mental health sessions, although providers and patients may discuss problems not contained
within the stop code designation. At 6 months, 1 year, and 2 years, respectively, means for
substance use disorder treatment sessions were 10.0 (SD=11.6), 6.6 (SD=12.4), and 12.0
(SD=25.6), and means for mental health treatment were 18.1 (SD=20.3), 14.1 (SD=19.1), and
22.6 (SD=30.2), respectively.
Mutual-help group participation. At follow-ups, to assess mutual-help group participation
since the previous assessment, we used the Alcoholics Anonymous Inventory (Tonigan, Conners,
& Miller, 1996, 2002) and Alcoholics Anonymous Affiliation Scale (Humphreys, Kaskutas, &
Weisner, 1998) (replacing “AA” with “12-step mutual-help group”). Together, these measures
assess both attendance and level of involvement. The 6-month and 1-year interviews asked about
mutual-help group participation over the past 6 months, and the 2-year interview asked about the
past year.
Attendance at mutual-help groups was highest at 6-month follow-up, with 76% having
attended at least one meeting, while 68% had attended at least one meeting at 1-year follow-up
and 67% at 2-year follow-up. Participants reported attending an average of 49.3 mutual-help
group meetings between baseline and the 6-month follow-up (SD=72.7), 41.6 meetings between
the 6-month and 1-year follow-up (SD=66.7) and 60.9 meetings between the 1-year and 2-year
follow-up (SD=91.9). They also reported their overall involvement in mutual-help groups,
which was the sum of 14 involvement items (0=no, 1=yes; e.g., did service at meetings, had a
sponsor), at 6 months (M=6.1, SD=4.5; Cronbach’s α=.92), 1 year (M=4.6, SD=4.5; α=.92), and
2 years (M=5.7, SD=4.8; α=.94).
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Substance use and psychiatric status. At each follow-up, participants completed the same
measures as at baseline. During the past 30 days, number of days of alcohol and drug use, and
number of psychiatric symptoms were assessed using the ASI.

Analysis Plan
We first examined correlations between patients’ baseline demographic and clinical
characteristics and subsequent mutual-help group participation (meeting attendance and
involvement), to determine whether any of these variables should be controlled for in subsequent
analyses (Kelly, Stout, Zywiak, & Schneider, 2006; Timko, Billow, & DeBenedetti, 2006). We
then examined intercorrelations of treatment amounts, mutual-help group participation, and
outcomes. Mixed model regressions were used to examine substance use (alcohol and drug days)
and psychiatric outcomes as a function of the baseline value of the outcome, treatment amounts
and mutual-help group participation, with a random intercept term for each participant. For all
regressions, independent variables included the baseline value of the outcome, number of
outpatient sessions of substance use disorder and mental health treatment, and the two indicators
of mutual-help group participation (number of meetings attended, overall involvement). All
analyses were conducted using PASW Statistics (version 18.0).
RESULTS

Correlations of Baseline Characteristics with Mutual-Help Group Participation
Baseline demographic (gender, race and ethnicity, age, employment status, marital status,
education) and clinical (presence of specific psychiatric and substance use disorder diagnoses in
the medical record, and total number of diagnoses) characteristics were not associated with

Dual Diagnosis, Mutual-Help Use, and Outcomes

10

mutual-help group participation, with two exceptions: employed patients attended fewer mutualhelp group meetings between the 6-month and 1-year follow-ups (r = -0.17, p = 0.01) , and
participants from racial and ethnic minority groups attended fewer meetings between the 1- and
2-year follow-ups (r = -0.15, p = 0.03). Due to the lack of consistent associations of patients’
demographic and clinical characteristics with mutual-help group participation, we did not control
for these characteristics in subsequent analyses.

Intercorrelations of Predictors and Outcomes
At all follow-ups, more mutual-help group meeting attendance and involvement were
significantly associated with fewer days of alcohol use. At 6-month and 2-year follow-ups, more
mutual-help group meeting attendance was also associated with fewer days of drug use; and at 6month and 1-year follow-ups, more mutual-help group involvement was associated with fewer
days of drug use. There were no significant correlations between mutual-help group meeting
attendance or involvement and psychiatric symptoms (Table 1). In general, outpatient substance
use disorder treatment, but not mental health treatment, was associated with more mutual-help
group participation.

Mixed Model Regressions Predicting Substance Use and Psychiatric Outcomes
With the baseline value of number of days of alcohol use and the amount of substance
use disorder treatment controlled, there was a significant effect of mental health treatment on
alcohol use, such that more treatment was associated with fewer days of use, F(1, 650.17) = 4.58,
p = 0.03. In addition, more mutual-help group attendance, F(1, 692.99) = 13.98, p < 0.001, and
involvement, F(1, 602.72) = 19.32, p < 0.001, were associated with less alcohol use. Similarly,
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with baseline drug use and treatment amounts considered, more mutual-help group attendance,
F(1, 652.82) = 4.57, p = 0.03, and involvement, F(1, 504.35) = 5.94, p =0.02, were associated
with fewer days of drug use. Amount of substance use disorder treatment was not associated with
outcomes. In addition, neither treatment amounts nor mutual-help group participation were
associated with psychiatric outcomes (Table 2).
DISCUSSION

We found that more mutual-help group participation by outpatients with dual diagnoses
was associated with better substance use outcomes over two years, above and beyond amounts of
treatment received. In contrast, mutual-help group participation was not associated with
psychiatric outcomes. Of particular interest was that more overall involvement in mutual-help
groups was associated with fewer alcohol- and drug-using days, suggesting that facilitating
involvement in mutual-help groups, in addition to simply attending more meetings, may be
beneficial to the recovery of patients with dual diagnoses.
Among patients with only substance use disorders, mutual-help group participation
contributes to substance use outcomes independent of treatment (Moos et al., 2001; Ouimette et
al., 1998). Our results extend these findings to a sample of individuals with dual diagnoses.
Significant associations were not found between mutual-help group participation and psychiatric
symptoms. For individuals with dual diagnoses, participation in dual-focused mutual-help
groups, such as Double Trouble in Recovery, may be helpful to reduce psychiatric symptoms
(Magura, 2008).
Number of mutual-help group meetings and overall mutual-help group involvement both
were associated with improved outcomes. For individuals with dual diagnoses, encouraging
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more meeting attendance may be helpful. In addition, involvement in 12-step practices, such as
connecting with other members including a sponsor, may be important above and beyond
meeting attendance (Kaskutas, Subbaraman, Witbrodt, & Zemore, 2009; Timko & DeBenedetti,
2007).
We found that amounts of substance use disorder and mental health outpatient treatment
had little association with outcomes. The content of sessions, which we did not assess, may have
more of an influence on substance use and psychiatric outcomes than amount of treatment (Hulse
& Tait, 2002). In addition, participants in the current study received parallel substance use
disorder and mental health treatment, and received more mental health than substance use
disorder treatment, which is common in the VA system (Hoff & Rosenheck, 1998; Kerfoot,
Petrakis, & Rosenheck, 2011). Better outcomes may be seen with integrated treatment
(Granholm, Anthenelli, Monteiro, Sevik, & Stoler, 2003).

Limitations
Patients in this study were treated within the VA, which is federally funded and operates
the largest mental health treatment system in the US. Generally, VA substance use disorder and
mental health disorder services are of similar quality and effectiveness to those in the private
sector (Asch, Lofgren, VanRuiswyk, & Layde, 2000; Rosenheck, Desai, Steinwachs, & Lehman,
2000). However, the VA patient population has poorer health status than the general patient
population (Agha et al., 2000; Grella, Stein, Weisner, Chi, & Moos, 2010).
Although we considered potential confounders of associations between mutual-help
group participation and substance use outcomes (baseline characteristics, problem severity, and
treatment amounts), there may be other variables not assessed in the current study that influence
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associations between mutual-help group participation and outcomes (Kelly et al., 2006, Timko et
al., 2006). Except for the treatment amount data, all of our measures were self-report. Some
studies support the validity of self-reports of alcohol and drug use (Babor, Stephan, & Marlatt,
1987; Calhoun et al., 2000; Darke, 1998; Hersh, Mulgrew, Van Kirk, & Kranzler, 1999;
Ouimette, Ahrens, Moos, & Finney, 1997), but others do not (Lundy et al., 1997; Magura, 2010;
Magura & Kang, 1996). Additional sources of information regarding substance use would be
useful for future studies. A more detailed measure of psychiatric symptoms would also be of use
in future research. Although the validity of our measure of psychiatric symptoms has some
support (Angarita et al., 2007; Timko et al., 2013), it is certainly limited in scope. Finally, future
studies should also consider documenting treatment session content.

Conclusions
We found that the benefits of mutual-help group participation for patients with dual
diagnoses were obtained for substance use outcomes even when treatment amounts were
considered. Because mutual-help group meeting attendance and involvement in 12-step practices
may be important components of the treatment plan for individuals with dual diagnoses,
providers should consider facilitating participation in mutual-help groups during treatment
(Kaskutas et al., 2009; Timko & DeBenedetti, 2007).
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Table 1
Intercorrelations Among Treatment, Mutual-Help Group Participation, and Outcomes
1

2

3

4

5

6-month follow-up
1. Outpatient MH Treatment
-0.140*
-0.028
-0.094
-0.058
2. Outpatient SUD Treatment
-0.218**
0.235*** -0.089
3. MHG Meetings
-0.552*** -0.135*
4. MHG Involvement
--0.165*
5. Alcohol Days
-6. Drug Days
7. Psychiatric Symptoms
1-year follow-up
1. Outpatient MH Treatment
-0.124
-0.089
-0.155*
-0.040
2. Outpatient SUD Treatment
-0.124
0.175**
-0.114
3. MHG Meetings
-0.616*** -0.171**
4. MHG Involvement
--0.272***
5. Alcohol Days
-6. Drug Days
7. Psychiatric Symptoms
2-year follow-up
1. Outpatient MH Treatment
-0.177** -0.039
-0.034
-0.222**
2. Outpatient SUD Treatment
-0.256*** 0.303*** -0.107
3. MHG Meetings
-0.665*** -0.148*
4. MHG Involvement
--0.140*
5. Alcohol Days
-6. Drug Days
7. Psychiatric Symptoms
Note. SUD = substance use disorder, MH = mental health, MHG = mutual-help group
*p < 0.05, ** p < 0.01, *** p < 0.001

6

7

-0.016
-0.092
-0.142*
-0.190**
0.148*
--

0.077
-0.028
-0.028
-0.110
0.128
0.125
--

0.092
-0.092
-0.086
-0.134*
0.152*
--

0.050
-0.063
-0.128
-0.130
0.093
0.117
--

-0.144*
-0.099
-0.133*
-0.099
0.275***
--

0.128
0.007
-0.087
-0.101
0.159*
0.341***
--
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Table 2
Estimated Effects of Treatment and Mutual-Help Group Participation on Outcomes
Alcohol Days
Parameter

Drug Days

Psychiatric Symptoms

Est.

SE

95% CI

Est.

SE

95% CI

Est.

SE

95% CI

Intercept

2.770***

0.400

1.984 – 3.556

2.495***

0.442

1.627 – 3.364

1.162***

0.131

0.904 – 1.420

Baseline Value of Outcome

0.228***

0.052

0.124 – 0.331

0.176***

0.037

0.103 – 0.249

0.410***

0.047

0.317 – 0.503

SUD Treatment

-0.005

0.011

-0.028 – 0.018

-0.016

0.014

-0.044 – 0.012

-0.004

0.003

-0.010 – 0.001

MH Treatment

-0.020*

0.009

-0.039 – -0.001

-0.017

0.011

-0.039 – 0.006

0.002

0.002

-0.002 – 0.007

MHG Meetings

-0.011***

0.003

-0.017 – -0.005

-0008*

0.004

-0.015 – -0.001

-0.001

0.001

-0.002 – 0.001

MHG Involvement

-0.243***

0.055

-0.353 – -0.135

-0.157*

0.064

-0.283 – -0.030

-0.014

0.013

-0.039 – 0.011

14.346***

2.167

10.669 – 19.289

11.175***

2.696

6.964 – 17.932

0.704***

0.107

0.522 – 0.948

Intercept Variance

Note. For all models, df = 6; SUD = Substance Use Disorder, MH = mental health, MHG = mutual-help group, Est = estimate, SE =
standard error, CI = confidence interval.
*p < 0.05, ** p < 0.01, *** p < 0.001

